An Open-Label Exploratory Study with Memantine: Correlation between Proton Magnetic Resonance Spectroscopy and Cognition in Patients with Mild to Moderate Alzheimer's Disease

被引：0
|
作者：
Gordon, Marc [1 ]
Kingsley, Peter [2 ]
Goldberg, Terry
Koppel, Jeremy
Christen, Erica
Keehlisen, Lynda
Kohn, Nina [3 ]
Davies, Peter
机构：
[1] N Shore LIJ Hlth Syst, Litwin Zucker Res Ctr, Neurol & Psychiat, Manhasset, NY USA
[2] N Shore LIJ Hlth Syst, Radiol, Manhasset, NY USA
[3] N Shore LIJ Hlth Syst, Biostat, Manhasset, NY USA
来源：
NEUROLOGY | 2012年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P04198
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Alzheimer's disease and the hippocampus: A proton magnetic resonance spectroscopy study
    Engelhardt, E
    Laks, J
    Moreira, D
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S473 - S473
  • [22] Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study
    Choi, Seong Hye
    Park, Kyung Won
    Na, Duk L.
    Han, Hyun Jeong
    Kim, Eun-Joo
    Shim, Yong S.
    Lee, Jae-Hong
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (07) : 1375 - 1383
  • [23] Safety and Tolerability of Extended-Release Memantine (Once Daily, 28 mg) in Patients with Moderate to Severe Alzheimer's Disease: An Open-Label Extension Study
    Alva, Gustavo
    Grossberg, George T.
    Manes, Facundo
    Allegri, Ricardo
    Guttierez Robledo, Luis Miguel
    Gloger, Sergio
    Xie, Lei
    Jia, Xinwei Daniel
    Perhach, James L.
    Graham, Stephen M.
    NEUROLOGY, 2010, 74 (09) : A394 - A395
  • [24] An exploratory, open-label study of secukinumab in patients with moderate to severe papulopustular rosacea
    Kumar, Anusha M.
    Chiou, Albert S.
    Shih, Yi-hsien
    Li, Shufeng
    Chang, Anne Lynn S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB88 - AB88
  • [25] A Long-Term, Open-Label Extension Study Evaluating the Safety of Extended-Release Memantine (28 mg) in Patients with Moderate to Severe Alzheimer's Disease
    Graham, Stephen M.
    Perhach, James
    ANNALS OF NEUROLOGY, 2011, 70 : S59 - S59
  • [26] A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer’s Disease in Taiwan
    Chiung-Chih Chang
    Giia-Sheun Peng
    Te-Jen Lai
    Chien-Hsun Li
    Ching-Kuan Liu
    Advances in Therapy, 2019, 36 : 1455 - 1464
  • [27] Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study
    Salloway, Stephen
    Marshall, Gad A.
    Lu, Ming
    Brashear, H. Robert
    CURRENT ALZHEIMER RESEARCH, 2018, 15 (13) : 1231 - 1243
  • [28] The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer's Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
    Yatawara, Chathuri
    Zailan, Fatin Zahra
    Chua, Esther Vanessa
    Lim, Linda Lay Hoon
    Silva, Eveline
    Wang, Joanna Sihan
    Ng, Adeline
    Ng, Kok Pin
    Kandiah, Nagaendran
    CLINICAL INTERVENTIONS IN AGING, 2021, 16 : 301 - 309
  • [29] A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer's Disease in Taiwan
    Chang, Chiung-Chih
    Peng, Giia-Sheun
    Lai, Te-Jen
    Li, Chien-Hsun
    Liu, Ching-Kuan
    ADVANCES IN THERAPY, 2019, 36 (06) : 1455 - 1464
  • [30] An Open-Label Extension Study Evaluating the Safety and Tolerability of Extended-Release Memantine (Once Daily, 28 Mg) in Patients with Moderate to Severe Alzheimer's Disease
    Alva, Gustavo
    Grossberg, George T.
    Manes, Facundo
    Allegri, Ricardo
    Gutierrez Robledo, Luis Miguel
    Gloger, Sergio
    Xie, Lei
    Jia, Xinwei D.
    Perhach, James L.
    Graham, Stephen M.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2010, 18 (03): : S72 - S73
12345